Literature DB >> 27021020

RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.

Chunling Jiang1,2, Tao Song3, Jingao Li2, Fan Ao2, Xiaochang Gong2, Yicheng Lu4, Chenran Zhang4, Liangyu Chen5, Yunhui Liu5, Hua He6, Ouping Huang7.   

Abstract

In this study, we investigated the influence of elevated RAS expression on the growth of meningioma in vivo and in vitro. The IOMM-LEE cells, representing a cell line derived from malignant meningioma, were divided into blank control group (cells without any drug treatment), negative control group (cells treated with an equal volume of normal saline to replace drug), and farnesyl thiosalicylic acid (FTS)-treated group (cells treated with FTS). Methyl-thiazole-tetrazolium bromide (MTT) assay and flow cytometer (with cells after FTS (75 μmol/L) treatment for 48 h) were utilized to determine the proliferation and apoptosis, respectively, of IOMM-LEE cells after RAS inhibition. Western blot analysis was used for semi-quantitative analysis of p-ERK and p-AKT levels. Animal model of human meningioma was established with sub-renal capsule transplantation, and mice were divided into two groups: experimental group (50 mg/kg group, 75 mg/kg group, and 100 mg/kg, hypodermic injection with FTS) and control group. Proliferating cell nuclear antigen (PCNA) was detected by immunohistochemistry (IHC). Western blot analysis was used for detecting ERK and AKT signal pathway. The proliferation of IOMM-LEE cells decreased dramatically and apoptosis rate increased significantly in FTS-treated group compared to blank control group and negative control group (all P < 0.05). At FTS concentration of 75 μmol/L, the apoptosis rate of IOMM-LEE cells reduced significantly over time (P < 0.05). Cell cycle analysis showed that IOMM-LEE cells exhibited G1-arrest in the FTS-treated group, compared to no cell-cycle arrest in blank control group and the negative control group (P < 0.05). Further, significantly decreased ERK and AKT phosphorylation levels were detected in IOMM-Lee cells after FTS (75 μmol/L) treatment for 48 h, compared to blank control group and negative control group (P < 0.05). The results in vivo experiments showed that after FTS treatment, tumor volume, PCNA LI, and the levels of p-ERK and p-Akt decreased significantly in 75 mg/kg group and 100 mg/kg group when compared with the control group and 50 mg/kg group (all P < 0.05). Our findings provide strong evidence that RAS protein is highly expressed in meningioma cells, and the RAS activity is inhibited by downregulating ERK and AKT signal pathway, which may further inhibit the growth of meningioma.

Entities:  

Keywords:  AKT protein; ERK protein; IOMM-LEE; Meningioma; RAS protein

Mesh:

Substances:

Year:  2016        PMID: 27021020     DOI: 10.1007/s12035-016-9763-z

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  32 in total

1.  Ink4a/Arf loss promotes tumor recurrence following Ras inhibition.

Authors:  Matthew W Vanbrocklin; James P Robinson; Kristin J Lastwika; Andrea J McKinney; H Michael Gach; Sheri L Holmen
Journal:  Neuro Oncol       Date:  2011-10-20       Impact factor: 12.300

2.  Pathway discovery: the road to Ras and MAP kinase.

Authors:  Chris Marshall
Journal:  Nat Cell Biol       Date:  2012-10       Impact factor: 28.824

Review 3.  Hyperactive Ras in developmental disorders and cancer.

Authors:  Suzanne Schubbert; Kevin Shannon; Gideon Bollag
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

4.  Proton stereotactic radiosurgery for the treatment of benign meningiomas.

Authors:  Lia M Halasz; Marc R Bussière; Elizabeth R Dennis; Andrzej Niemierko; Paul H Chapman; Jay S Loeffler; Helen A Shih
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-08       Impact factor: 7.038

Review 5.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Authors:  Dominico Vigil; Jacqueline Cherfils; Kent L Rossman; Channing J Der
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

6.  Recurrence of intracranial meningioma after surgery: analysis of influencing factors and outcome.

Authors:  Pakpume Bumrungrachpukdee; Nannapat Pruphetkaew; Manlika Phukaoloun; Nakornchai Pheunpathom
Journal:  J Med Assoc Thai       Date:  2014-04

Review 7.  Targeting the RAS oncogene.

Authors:  Asami Takashima; Douglas V Faller
Journal:  Expert Opin Ther Targets       Date:  2013-01-30       Impact factor: 6.902

8.  Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.

Authors:  Tapan M Kadia; Hagop Kantarjian; Steven Kornblau; Gautam Borthakur; Stefan Faderl; Emil J Freireich; Raja Luthra; Guillermo Garcia-Manero; Sherry Pierce; Jorge Cortes; Farhad Ravandi
Journal:  Cancer       Date:  2012-05-08       Impact factor: 6.860

9.  Ras activation induces expression of Raet1 family NK receptor ligands.

Authors:  Xi V Liu; Samantha S W Ho; James J Tan; Neha Kamran; Stephan Gasser
Journal:  J Immunol       Date:  2012-07-13       Impact factor: 5.422

10.  Subtle clinical signs of a meningioma in an adult: a case report.

Authors:  Andrée-Anne Marchand; Julie O'Shaughnessy
Journal:  Chiropr Man Therap       Date:  2014-02-04
View more
  5 in total

1.  Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.

Authors:  Francesco Pepe; Pasquale Pisapia; Maria Laura Del Basso de Caro; Floriana Conticelli; Umberto Malapelle; Giancarlo Troncone; Juan Carlos Martinez
Journal:  Histol Histopathol       Date:  2019-12-24       Impact factor: 2.303

2.  Acarbose attenuates migration/proliferation via targeting microRNA-143 in vascular smooth muscle cells under diabetic conditions.

Authors:  Wei-Yuan Chuang; Meng-Hsun Yu; Tsung-Yuan Yang; Kuei-Chuan Chan; Chau-Jong Wang
Journal:  J Food Drug Anal       Date:  2020-09-15       Impact factor: 6.157

3.  Di2-ethylhexyl phthalate disrupts thyroid hormone homeostasis through activating the Ras/Akt/TRHr pathway and inducing hepatic enzymes.

Authors:  Hanfeng Ye; Mei Ha; Min Yang; Ping Yue; Zhengyuan Xie; Changjiang Liu
Journal:  Sci Rep       Date:  2017-01-09       Impact factor: 4.379

4.  Resveratrol Inhibits Proliferation in HBL-52 Meningioma Cells.

Authors:  Shun-An Hu; Wei Wei; Jia Yuan; Jin Cheng
Journal:  Onco Targets Ther       Date:  2019-12-30       Impact factor: 4.147

Review 5.  Molecular Mechanism and Approach in Progression of Meningioma.

Authors:  Zhiwei Shao; Lihong Liu; Yanghao Zheng; Sheng Tu; Yuanbo Pan; Sheng Yan; Qichun Wei; Anwen Shao; Jianmin Zhang
Journal:  Front Oncol       Date:  2020-09-11       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.